Blueprint Medicines (BPMC) Revenue & Revenue Breakdown
Blueprint Medicines Revenue Highlights
Latest Revenue (Y)
$249.38M
Latest Revenue (Q)
$138.16M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Blueprint Medicines Revenue by Period
Blueprint Medicines Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $249.38M | 22.22% |
| 2022-12-31 | $204.04M | 13.30% |
| 2021-12-31 | $180.08M | -77.31% |
| 2020-12-31 | $793.74M | 1093.37% |
| 2019-12-31 | $66.51M | 49.39% |
| 2018-12-31 | $44.52M | 107.79% |
| 2017-12-31 | $21.43M | -22.85% |
| 2016-12-31 | $27.77M | 143.61% |
| 2015-12-31 | $11.40M | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Blueprint Medicines generated $249.38M in revenue during NA 2023, up 22.22% compared to the previous quarter, and up 560.14% compared to the same period a year ago.
Blueprint Medicines Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $138.16M | 43.74% |
| 2024-03-31 | $96.12M | 33.57% |
| 2023-12-31 | $71.96M | 27.21% |
| 2023-09-30 | $56.57M | -1.74% |
| 2023-06-30 | $57.57M | -9.03% |
| 2023-03-31 | $63.29M | 63.19% |
| 2022-12-31 | $38.78M | -41.22% |
| 2022-09-30 | $65.98M | 80.53% |
| 2022-06-30 | $36.55M | -41.74% |
| 2022-03-31 | $62.73M | -41.38% |
| 2021-12-31 | $107.02M | 342.46% |
| 2021-09-30 | $24.19M | -11.38% |
| 2021-06-30 | $27.30M | 26.51% |
| 2021-03-31 | $21.58M | -36.74% |
| 2020-12-31 | $34.11M | -95.42% |
| 2020-09-30 | $745.12M | 8831.06% |
| 2020-06-30 | $8.34M | 35.28% |
| 2020-03-31 | $6.17M | -88.03% |
| 2019-12-31 | $51.53M | 463.88% |
| 2019-09-30 | $9.14M | 78.85% |
| 2019-06-30 | $5.11M | 600.00% |
| 2019-03-31 | $730.00K | -29.33% |
| 2018-12-31 | $1.03M | -5.66% |
| 2018-09-30 | $1.09M | -97.36% |
| 2018-06-30 | $41.44M | 4243.71% |
| 2018-03-31 | $954.00K | -41.40% |
| 2017-12-31 | $1.63M | -79.82% |
| 2017-09-30 | $8.07M | 36.98% |
| 2017-06-30 | $5.89M | 0.86% |
| 2017-03-31 | $5.84M | -24.07% |
| 2016-12-31 | $7.69M | 24.85% |
| 2016-09-30 | $6.16M | -12.81% |
| 2016-06-30 | $7.07M | 3.05% |
| 2016-03-31 | $6.86M | 47.92% |
| 2015-12-31 | $4.63M | 35.29% |
| 2015-09-30 | $3.43M | 27.50% |
| 2015-06-30 | $2.69M | 312.12% |
| 2015-03-31 | $652.00K | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | - |
Blueprint Medicines generated $138.16M in revenue during Q2 2024, up 43.74% compared to the previous quarter, and up 218.30% compared to the same period a year ago.
Blueprint Medicines Revenue Breakdown
Blueprint Medicines Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Product | $204.21M | $110.99M | $22.13M | - |
| AYVAKIT and AYVAKYT | $204.21M | $52.98M | - | - |
| GAVRETO | - | - | $4.71M | - |
| Product revenue, net | - | - | $57.69M | - |
| Collaboration | - | - | - | $771.60M |
Blueprint Medicines's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (50.00%), and AYVAKIT and AYVAKYT (50.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration and License | $24.04M | $3.59M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | $114.11M | $125.26M | $39.88M | $39.07M | $30.06M | $8.96M | $6.69M | $6.31M | $5.68M | $3.46M | - | - | - | - | - | - | - |
| Royalty | - | $198.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration revenue | - | $1.94M | $15.86M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| AYVAKIT and AYVAKYT | - | - | $134.97M | $34.31M | $34.93M | $30.06M | $28.63M | $28.45M | $23.84M | $20.03M | $17.27M | - | - | - | - | - | - |
| GAVRETO | - | - | - | $5.57M | $4.14M | - | $4.71M | - | - | - | - | - | - | - | - | - | - |
| Product revenue, net | - | - | - | - | - | - | $28.63M | $28.45M | $23.84M | $20.03M | $17.27M | $11.43M | - | - | - | - | - |
| Collaboration | - | - | - | - | - | - | - | - | - | - | - | - | $12.62M | $27.42M | $738.81M | $2.66M | $2.71M |
Blueprint Medicines's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (82.60%), and Collaboration and License (17.40%).
Blueprint Medicines Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 |
|---|---|---|
| Non-US | $22.24M | $13.77M |
| UNITED STATES | $181.97M | $97.23M |
Blueprint Medicines's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (89.11%), and Non-US (10.89%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 |
|---|---|---|
| UNITED STATES | $101.46M | $83.14M |
| Non-US | $12.65M | $9.39M |
Blueprint Medicines's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (88.91%), and Non-US (11.09%).
Blueprint Medicines Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| MREO | Mereo BioPharma Group | $10.00M | - |
| KRTX | Karuna Therapeutics | $654.00K | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
BPMC Revenue FAQ
What is Blueprint Medicines’s yearly revenue?
Blueprint Medicines's yearly revenue for 2023 was $249.38M, representing an increase of 22.22% compared to 2022. The company's yearly revenue for 2022 was $204.04M, representing an increase of 13.30% compared to 2021. BPMC's yearly revenue for 2021 was $180.08M, representing a decrease of -77.31% compared to 2020.
What is Blueprint Medicines’s quarterly revenue?
Blueprint Medicines's quarterly revenue for Q2 2024 was $138.16M, a 43.74% increase from the previous quarter (Q1 2024), and a 139.98% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $96.12M, a 33.57% increase from the previous quarter (Q4 2023), and a 51.87% increase year-over-year (Q1 2023). BPMC's quarterly revenue for Q4 2023 was $71.96M, a 27.21% increase from the previous quarter (Q3 2023), and a 85.55% increase year-over-year (Q4 2022).
What is Blueprint Medicines’s revenue growth rate?
Blueprint Medicines's revenue growth rate for the last 3 years (2021-2023) was 38.48%, and for the last 5 years (2019-2023) was 274.94%.
What are Blueprint Medicines’s revenue streams?
Blueprint Medicines's revenue streams in c 23 are Product, and AYVAKIT and AYVAKYT. Product generated $204.21M in revenue, accounting 50.00% of the company's total revenue, up 83.98% year-over-year. AYVAKIT and AYVAKYT generated $204.21M in revenue, accounting 50.00% of the company's total revenue, up 285.43% year-over-year.
What is Blueprint Medicines’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Blueprint Medicines was Product. This segment made a revenue of $204.21M, representing 50.00% of the company's total revenue.